this superpotent analog is now entering a phase i clinical trial with possible therapeutic applications for the treatment of hypomelanotic disorders such as vitiligo and for pharmacologic tanning without the need for sunlight exposure .
C0162835
hypomelanotic
C0042900
vitiligo